The prospects for targeting CD83 on MCL patients requires identification of CD83+ MCL patients, application of the most recent ADC techniques to generate anti‐CD83 ADC and the combination of ADC with current chemotherapy. The gene discussed is CD83; the disease is mantle cell lymphoma.